Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Abbott Aims at Top Share in DES Market in Japan with XIENCE V
February 15, 2010
- Kyowa Kirin to Jointly Distribute KW-2246 with Hisamitsu
February 15, 2010
- RDKK to Launch K-RAS Gene Mutation Test Kit in April
February 15, 2010
- Wakunaga to Build New Plant in California
February 15, 2010
- Nipro to Acquire Home Diagnostics of the US
February 15, 2010
- Generics Priced Higher Than Original Drugs Should Not Be Regarded as Generics: Korosho
February 15, 2010
- HSTTC Mediates Transfer of NCC-Developed Technology to MKI
February 15, 2010
- Only 2% of Current Non-Users to Start Prescribing Rasilez: SSRI
February 15, 2010
- Panel to Review Drugs, Indications That Need Development
February 15, 2010
- 3rd Candidate for JMA President
February 15, 2010
- Takeda to Work Out New Mid-Term Management Plan 1 Year Ahead of Schedule
February 15, 2010
- Daiichi Sankyo Applies for Laninamivir in Japan
February 15, 2010
- JAID Compiles Guidance for Selection of Anti-Flu Drugs
February 15, 2010
- Chugai Aims to Lead Market in 3 Fields: Mr Nagayama
February 15, 2010
- Urief Approved in Europe: Kissei
February 15, 2010
- Smoking Cessation Aids Should Be Covered by Insurance in Young Smokers
February 15, 2010
- Collect Clinically Significant PGx Evidence: Dr Uyama
February 8, 2010
- Kaken to Take Over Marketing of Synphase from Tsumura
February 8, 2010
- 4 Class C2 Med Devices Recommended for Reimbursement
February 8, 2010
- Astellas Transfers Yet Another Product to Choseido
February 8, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…